CD19-targeted CD3×CD19 BiTE lentiviral vector

CD19-targeted CD3×CD19 BiTE lentiviral vector is an innovative in vivo gene therapy platform developed by Immunofoco in collaboration with Renji Hospital and Shanghai East Hospital. The therapy utilizes an engineered lentiviral vector pseudotyped with a CD19-targeting envelope to selectively transduce CD19-positive lymphoma cells and B cells in vivo. Once transduced, these cells are reprogrammed into 'in situ factories' that continuously secrete a functional CD3×CD19 bispecific T-cell engager (BiTE). The locally produced BiTE recruits and activates T cells to eliminate both the transduced cells and neighboring untransduced CD19-positive tumor cells via a bystander killing effect. This approach aims to overcome the limitations of conventional recombinant BiTE therapies, such as short half-life and systemic toxicities, by enabling sustained local production of the therapeutic protein directly within the tumor microenvironment.